Prescription Drug Supply Chain Pricing Transparency Act

# Prescription Drug Supply Chain Pricing Transparency Act Summary **What the Bill Would Do** This bill would require companies involved in the prescription drug supply chain—including manufacturers, wholesalers, and pharmacy benefit managers (PBMs)—to disclose detailed pricing information. The goal is to increase transparency about how drug prices are set and what happens to costs as medications move from manufacturers to patients at pharmacies. By making this pricing data public, the bill aims to help identify where money goes in the drug distribution system and potentially uncover practices that drive up costs. **Who It Affects** The primary targets are pharmaceutical companies, drug wholesalers, and PBMs (the middlemen who manage drug benefits for insurance plans).

Secondarily, it could affect patients and insurance companies by providing clearer information about drug pricing. Lawmakers and researchers would also benefit from access to this pricing data when developing future healthcare policies. **Current Status** The bill was introduced in the 119th Congress but remains in committee, meaning it has not yet been debated or voted on by the full Senate. Bills at this stage may be revised, die in committee, or eventually advance for consideration, depending on lawmakers' priorities.